46 results about "Hematopoietic progenitor" patented technology

A method is provided for recruiting hematopoietic progenitor cells from the bone marrow of a target to the peripheral blood. The method comprises (a) administering an effective dose of natalizumab to the target, and (b) administering an effective dose of a CXCR4 inhibitor to the target, at least 48 hours after step (a). The use of such recruitment procedures in cell collection and therapy is also provided.

The present invention provides a novel method for producing natural killer (NK) cells, which enables production of a large amount of high-quality NK cells easily, inexpensively, and safely in a short period of time from pluripotent stem cells. Specifically, a method for producing NK cells is provided, including(1) a step of forming pluripotent stem cell spheres having an average particle size of not less than 200 μm in a first medium;(2) a step of inducing the pluripotent stem cell spheres formed in step (1) into a cell population including hematopoietic progenitor cells by three-dimensional culture using a second medium; and(3) a step of inducing the cell population including hematopoietic progenitor cells obtained in step (2) into a cell population including NK cells by three-dimensional culture using a third medium,wherein the steps (1) to (3) are performed by a perfusion culture method.

The identification of differentiation stages, differentiation trajectories, and expression profiles of hematopoietic progenitor cells and fate-determining factors, and the application thereof are provided. The enrichment and identification of rare hematopoietic progenitor cells, as well as the identification of and their fate-determining genes, are also provided. A method for reconstructing hematopoietic hierarchy is provided, which includes fate-determining factors, differentiation trajectories, and patterns within lineage commitment processes.

The present disclosure provides methods for generating hematopoietic progenitor cells. In some embodiments, the methods involve an in vitro or ex vivo cell culture model utilizing rentionic acid signaling for producing hematopoietic progenitor cells from pluripotent stem cells.

The present invention relates to processes for the in vitro production of hematopoietic cells, comprising contacting hematopoietic progenitors with a DNTM3A inhibitor, hematopoietic cells comprising said DNTM3A inhibitor and uses thereof.

Disclosed herein are compounds that are Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

A method for alleviating fatigue, comprising administering to a patient in need thereof an effective amount of a human umbilical cord blood composition, which comprises hematopoietic progenitor cells, monocytes, lymphocytes, granulocytes, or a combination thereof.

The invention provides a smoke disease model and a construction method and application thereof, and belongs to the technical field of smoke disease model construction. The method for constructing the smog disease model comprises the following steps: extracting CD34 + hematopoietic progenitor cells in peripheral blood of a smog disease patient, reprogramming to generate hiPSC, further differentiating into brain organs and vascular organs, fusing the brain organs and the vascular organs, and culturing and constructing the vascularized brain organ smog disease model. The smoke disease model constructed by adopting the construction method disclosed by the invention can simulate and reproduce phenotypes such as tiny branch increase, macrovascularization, pericytopenia, smooth muscle fibrosis deposition, abnormal angiogenesis increase and the like in clinical core pathological phenotypes of smoke disease patients, and is superior to existing animal and cell models to a certain extent.

The present invention provides a method for producing a natural killer cell from an iPS (Induced pluripotent stem) cell, comprising steps of: (i) contacting an iPS cell with a composition comprising a GSK-3 inhibitor and a ROCK inhibitor to obtain an embryoid body, (ii) contacting the embryoid body with a composition comprising a TGFβ receptor inhibitor to obtain a hematopoietic progenitor cell, (iii) culturing the hematopoietic progenitor cell to obtain a lymphocyte progenitor cell, and (iv) differentiating and expanding the lymphocyte progenitor cells to a natural killer cell.

This invention discloses a method for co-culturing and inducing stem cell differentiation into hematopoietic progenitor cells. The method includes the following steps: culturing pluripotent stem cells to obtain embryoid bodies; culturing the embryoid bodies for mesodermal differentiation to obtain mesodermal cells; culturing the mesodermal cells for hematopoietic endothelial differentiation to obtain hematopoietic endothelial cells; and co-culturing the hematopoietic endothelial cells with mesenchymal stem cells to obtain hematopoietic progenitor cells. Through optimization of the culture system, the differentiation efficiency and the number of hematopoietic progenitor cells obtained are significantly improved; by co-culturing mesenchymal stem cells with hematopoietic endothelial cells, the number of hematopoietic progenitor cells is further increased while maintaining high differentiation efficiency and uniform and stable expression of various markers.

The invention discloses a trophoblast-free method for inducing human pluripotent stem cells to differentiate into hematopoietic cells in vitro, and belongs to the technical field of biology. The method comprises the following steps: firstly, culturing human pluripotent stem cells, digesting the cells, adding an embryoid to form a culture medium to prepare a cell suspension, inoculating the cell suspension to an agarose template with an inverted pyramid-shaped groove, culturing until an embryoid is formed, then adding an embryoid adherent culture medium, transferring to a culture dish which is bottomed by an extracellular matrix in advance, culturing until the embryoid adheres to the wall, and finally obtaining the human pluripotent stem cells. And a hematopoietic differentiation culture medium is used for inducing hematopoietic differentiation and generating ancestor cells of blood. The method disclosed by the invention has the advantages of simplicity, rapidness, economy and the like, can be used for rapidly and efficiently differentiating to obtain a large number of hematopoietic progenitor cells, is suitable for detection of hematopoietic differentiation potential and clinical application of differentiation to functional blood cells, can also be used for high-throughput large-scale screening of blood-related drugs, and has a relatively good application prospect.

The present disclosure relates to a method for induced differentiation of stem cells into hematopoietic progenitor cells. The method comprises the following steps: culturing pluripotent stem cells to obtain an embryoid body; performing mesoderm differentiation culture on the embryoid body to obtain mesoderm cells; performing hemogenic endothelium differentiation culture on the mesoderm cells to obtain hemogenic endothelial cells; and performing hematopoietic progenitor cell differentiation culture on the hemogenic endothelial cells to obtain hematopoietic progenitor cells. According to the present disclosure, the hematopoietic progenitor cells can be rapidly and efficiently prepared, and the prepared hematopoietic progenitor cells have an ability to stably differentiate into a plurality of different blood cells (including simultaneously having erythroid, myeloid, and lymphoid cells); by optimizing a culture system, the differentiation efficiency is significantly improved and the number of hematopoietic progenitor cells obtained is significantly increased.

The present disclosure provides methods for making bone marrow hematopoietic progenitors lacking NF-κB p50 protein subunit (p50) and STAT6, or bone marrow hematopoietic progenitors lacking NF-κB p50 protein subunit and NF-κB p52 protein subunit. The progenitor cells are expanded, exposed to a myeloid cytokine, and provided intravenously to treat various malignancies. The infused cells have the potential to generate mature granulocytes, monocytes, macrophages, and dendritic cells. Methods for the genetically manipulation of a subject's hematopoietic progenitors during the expansion phase to reduce or eliminate expression of p50, p52, and / or STAT6 are also contemplated, and these progenitor cells may be combined with other therapeutic agents to maximize efficacy.

The invention provides methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells. The methods include the use of chemically-defined culture media. Isolated cell populations are also provided.

The invention provides methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells. The methods include the use of chemically-defined culture media. Isolated cell populations are also provided.

The present invention provides a novel pyrazolo[3,4-b]pyridine derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition comprising same, and use thereof. The pyrazolo[3,4-b]pyridine derivative or the pharmaceutically acceptable salt thereof can be effectively applied in the treatment and prevention of various blood cancers or solid cancers through excellent inhibitory activity against hematopoietic progenitor kinase 1 (HPK1).

The method of generating multipotent stem cells is a method for producing and / or expanding multipotent stem cells by delivering at least one reprogramming protein into somatic cells. The at least one reprogramming protein includes a Master Regulator (MR) protein, which may be BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1. The bromodomain protein BAZ2B, in particular, was identified by first generating bi-species heterokaryons by fusing Tcf7l1− / − murine embryonic stem cells (ESCs) with human B-cell lymphocytes. Reprogramming of the B-cell nuclei to a multipotent state was tracked by human mRNA transcript profiling at multiple timepoints. Interrogation of a human B-cell regulatory network with gene expression signatures collected from such reprogramming time series identified eight candidate Master Regulator proteins, which were validated in human cord blood-derived hematopoietic progenitor and lineage-committed cells.

Methods and compositions for producing heterologous-free genes of hematopoietic progenitor cells and natural killer (NK) cells are provided.

The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.

Provided are compounds of formula (I), tautomers thereof, deuterated derivatives of the compounds or tautomers, and pharmaceutically acceptable salts of the foregoing, compositions comprising compounds of formula (I), tautomers thereof, deuterated derivatives of the compounds or tautomers, and / or pharmaceutically acceptable salts of the foregoing, and methods of using same in treating diseases, disorders, or conditions mediated by inhibition of protein kinases such as, for example, hematopoietic progenitor kinase 1 (HPK1, MAP4K1), human Fms-like tyrosine kinase 3 receptor (FLT3), and Aurora kinase. JPEG2025525278000046.jpg39170

A cell culturing method comprising culturing hematopoietic stem cells or hematopoietic progenitor cells, or both the hematopoietic stem cells and the hematopoietic progenitor cells with their undifferentiated state maintained using a device for cell culture. The device includes a base material having a culture section with a plurality of pores, wherein the culture section has a Young's modulus of at least 3 GPa measured according to JIS K 7161-1.

The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.

Compositions and methods for modulating the immune system generally include immunomodulatory exosomes derived from platelet-rich plasma that has been subjected to multiple freeze-thaw cycles and lyophilization. In one or more embodiments, the methods include administering the composition to a subject in an amount effective to modulate the immune system of the subject. In other embodiments, the methods include culturing hematopoietic progenitor cells or cells differentiated from hematopoietic progenitor cells with immunomodulatory exosomes to produce treated cells. The treated cells are then administered to the subject in an amount effective to modulate the immune system of the subject.

Provided are compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing, compositions comprising the compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing, and methods of using the same, in treating, for example, the diseases, disorders, or conditions mediated by the degradation of protein kinases, such as Hematopoietic progenitor kinase 1 (HPK1, MAP4K1), Mitogen-activated protein kinases 1 / 2 (MEK 1 / 2), Human Fms-like tyrosine kinase 3 receptor (FLT3), and Aurora kinases.